Answer
Mothers should not breastfeed during Enrylaze (recombinant crisantaspase) treatment or for two weeks after the last dose because of potential serious adverse reactions in breastfed infants or children.
Sources for this answer
- Enrylaze 10 mg/0.5 ml Solution for injection/infusionJazz Pharmaceuticals UK Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 2Document updated
Sources checked